Showing results (91-100 of 109) with videos related to
Sort By:
Pageof 11
British Journal of Cancer|November 1, 1989
A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinomaJ J Keating, P J Johnson, A M Cochrane, et al.Gynecologic Oncology|July 7, 2012
Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD aloneCarolyn N Krasner, Andres Poveda, Thomas J Herzog, et al.Gynecologic Oncology|November 20, 2009
Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumorsMaria R Roche, Pandora J Rudd, Carolyn N Krasner, et al.Cancer|July 16, 2016
Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancerMarcela G Del Carmen, Jeff G Supko, Nora K Horick, et al.Gynecologic Oncology|July 4, 2012
Phase II trial of erlotinib in women with squamous cell carcinoma of the vulvaN S Horowitz, A B Olawaiye, D R Borger, et al.International Journal of Clinical Oncology|April 21, 2010
Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancerSusana M Campos, Suzanne T Berlin, Leroy M Parker, et al.Medical Oncology (Northwood, London, England)|February 12, 2013
Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trialsJosé María del Campo, Cristiana Sessa, Carolyn N Krasner, et al.Journal of the National Cancer Institute|April 19, 2023
Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitorsShruti Gupta, Paul E Hanna, Tianqi Ouyang, et al.European Journal of Cancer (Oxford, England : 1990)|May 1, 2012
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysisBradley J Monk, Thomas J Herzog, Stanley B Kaye, et al.Clinical Ovarian Cancer and Other Gynecologic Malignancies|August 12, 2011
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian CarcinomaNeil S Horowitz, Richard T Penson, Dan G Duda, et al.Pageof 11